Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
|Articles|September 4, 2017
Should surgery be standard of care in uncomplicated appendicitis? (VIDEO)
Author(s)Bobby Lazzara, MD
For Contemporary Pediatrics, Dr Bobby Lazzara discusses a large study published in Pediatrics that examined what happened when children were nonsurgically managed for appendicitis, often with antibiotics, and compared the results with their peers who had received surgical treatment.
Advertisement
For Contemporary Pediatrics, Dr Bobby Lazzara discusses a large study published in Pediatrics that examined what happened when children were nonsurgically managed for appendicitis, often with antibiotics, and compared the results with their peers who had received surgical treatment.
Advertisement
Related to this article
Schools without stock epinephrine were over 4 times as likely to lack a device in an allergic emergency, a survey of 349 school nurses found.
In a matched cohort of children aged 6 and younger with EoE, dupilumab was linked to less incident asthma than swallowed budesonide (10.5% vs 16.2%).
Non-English-speaking families were far less likely to introduce peanut by 6 months (OR, 0.21) in a 3,170-child study presented at ACAAI 2026.
In an ACAAI 2026 survey, 85% of clinicians knew food allergy panels often yield false positives, yet many ordered them for unvalidated uses.
Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.
Classroom engagement scores in digital gradebooks predicted substance use by eighth grade better than GPA (cross-validated AUC, 0.79 vs 0.63).
Children living more than 60 miles from their surgical hospital had higher complication odds and longer stays after common procedures.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
How pediatricians can reframe vaccine conversations
2
Language barriers linked to lower early peanut introduction rates
3
FDA investigates malignancy risk with SMA gene therapy Zolgensma
4
Risankizumab shows 52-week efficacy in pediatric psoriasis trial
5